The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study.

Modern treatment, a healthy diet, and physical activity routines lower the risk factors for metabolic syndrome; however, this condition is associated with all-cause and cardiovascular mortality worldwide. This investigation involved a randomized controlled trial, double-blind, parallel study. Fifty-...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Wongsakorn Luangphiphat, Pinidphon Prombutara, Praewpannarai Jamjuree, Chantanapa Chantarangkul, Porntipha Vitheejongjaroen, Chantaluck Muennarong, Krittapat Fukfon, Manasvin Onwan, Malai Taweechotipatr
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Public Library of Science (PLoS) 2025-01-01
Seri Bilgileri:	PLoS ONE
Online Erişim:	https://doi.org/10.1371/journal.pone.0317202
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study.

Benzer Materyaller